Innate Pharma’s IPH6501 Trial: A Potential Game-Changer in Non-Hodgkin Lymphoma Treatment

Innate Pharma S.A. ((IPHYF)) announced an update on their ongoing clinical study.

Study Overview: Innate Pharma S.A. is conducting a Phase 1/2 clinical trial titled ‘A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients With Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma.’ The study aims to assess the safety and tolerability of IPH6501, a novel therapeutic, and to determine the recommended phase 2 dose for patients with this challenging condition.

Intervention/Treatment: The intervention being tested is IPH6501, an experimental drug designed to treat relapsed or refractory B-cell non-Hodgkin lymphoma. The study will explore its safety and optimal dosing in affected patients.

Study Design: This is an interventional study with a single-group assignment. It is open-label, meaning both researchers and participants know the treatment being administered. The primary purpose is treatment-focused, aiming to evaluate the drug’s effects on the condition.

Study Timeline: The study began on October 12, 2023, with an estimated primary completion date in March 2025. The last update was submitted on March 28, 2025, indicating ongoing recruitment and data collection.

Market Implications: The progress of this study could significantly impact Innate Pharma’s stock performance, as positive results may enhance investor confidence and market position. The study’s outcome could also influence the competitive landscape in the treatment of non-Hodgkin lymphoma, potentially affecting other companies in the oncology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.